Display options
Cite
Uemura M, Kim HM, Hata T, et al. First-line cetuximab-based chemotherapies for patients with advanced or metastatic . Mol Clin Oncol. 2016;5(2):375-379doi: 10.3892/mco.2016.938.
Uemura, M., Kim, H. M., Hata, T., Sakata, K., Okuyama, M., Takemoto, H., Fujii, H., Fukuzaki, T., Morita, T., Hata, T., Takemasa, I., Satoh, T., Mizushima, T., Doki, Y., Mori, M. (2016). First-line cetuximab-based chemotherapies for patients with advanced or metastatic . Molecular and clinical oncology, 5(2), 375-379. https://doi.org/10.3892/mco.2016.938
Uemura, Mamoru, et al. "First-line cetuximab-based chemotherapies for patients with advanced or metastatic ." Molecular and clinical oncology vol. 5,2 (2016): 375-379. doi: https://doi.org/10.3892/mco.2016.938
Uemura M, Kim HM, Hata T, Sakata K, Okuyama M, Takemoto H, Fujii H, Fukuzaki T, Morita T, Hata T, Takemasa I, Satoh T, Mizushima T, Doki Y, Mori M. First-line cetuximab-based chemotherapies for patients with advanced or metastatic . Mol Clin Oncol. 2016 Aug;5(2):375-379. doi: 10.3892/mco.2016.938. Epub 2016 Jun 17. PMID: 27446583; PMCID: PMC4950727.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2016 Aug;5(2):375-379. doi: 10.3892/mco.2016.938. Epub 2016 Jun 17.

First-line cetuximab-based chemotherapies for patients with advanced or metastatic .

Molecular and clinical oncology

Mamoru Uemura, Ho Min Kim, Tsuyoshi Hata, Kazuya Sakata, Masaki Okuyama, Hiroyoshi Takemoto, Hitoshi Fujii, Takayuki Fukuzaki, Tetsushi Morita, Taishi Hata, Ichiro Takemasa, Taroh Satoh, Tsunekazu Mizushima, Yuichiro Doki, Maski Mori,

Affiliations

  1. Department of Surgery, National Hospital Organization, Osaka National Hospital, Osaka 540-0006, Japan; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
  2. Department of Surgery, Osaka Rosai Hospital, Osaka 591-8025, Japan; Department of Surgery, Rinku General Medical Center, Osaka 598-8577, Japan.
  3. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
  4. Department of Surgery, Higashiosaka City General Hospital, Osaka 578-8588, Japan.
  5. Department of Surgery, Sakai City Medical Center, Osaka 593-8304, Japan.
  6. Department of Surgery, Rinku General Medical Center, Osaka 598-8577, Japan.
  7. Department of Surgery, Ikeda Municipal Hospital, Osaka 563-8510, Japan.
  8. Department of Surgery, Nissei Hospital, Osaka 550-0012, Japan.
  9. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; Department of Frontier-Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka 565-0871, Japan.

PMID: 27446583 PMCID: PMC4950727 DOI: 10.3892/mco.2016.938

Abstract

Colorectal cancer (CRC) is one of the most commonly occurring cancers worldwide. A burgeoning number of studies have demonstrated that the addition of cetuximab to another standard first-line regimen markedly improves the outcome of CRC treatment. However, at present, the efficacy and safety of cetuximab-based combination chemotherapy has not been well described in Japan. The aim of the present study was to evaluate the efficacy and safety of first-line chemotherapies that included cetuximab for patients with advanced or metastatic Kirsten rat sarcoma viral oncogene homolog (

Keywords: KRAS wild-type; cetuximab; colorectal cancer; first-line chemotherapy; irinotecan; oxaliplatin

References

  1. Surg Today. 2014 Aug;44(8):1457-64 - PubMed
  2. N Engl J Med. 2004 Jun 3;350(23 ):2335-42 - PubMed
  3. Lancet Oncol. 2010 Jan;11(1):38-47 - PubMed
  4. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 - PubMed
  5. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  6. Lancet Oncol. 2014 Sep;15(10):1065-75 - PubMed
  7. Lancet. 1998 Oct 31;352(9138):1407-12 - PubMed
  8. J Clin Oncol. 2009 Feb 10;27(5):663-71 - PubMed
  9. Lancet. 1998 Oct 31;352(9138):1413-8 - PubMed
  10. Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1688-94 - PubMed
  11. Ann Oncol. 2002 Apr;13(4):566-75 - PubMed
  12. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  13. N Engl J Med. 2004 Jul 22;351(4):337-45 - PubMed
  14. N Engl J Med. 2000 Sep 28;343 (13):905-14 - PubMed
  15. J Clin Oncol. 2004 Jan 1;22(1):23-30 - PubMed
  16. Lancet. 2000 Mar 25;355(9209):1041-7 - PubMed
  17. J Clin Oncol. 2004 Apr 1;22(7):1209-14 - PubMed
  18. N Engl J Med. 2009 Apr 2;360(14):1408-17 - PubMed
  19. Surg Today. 2016 Feb;46(2):161-8 - PubMed

Publication Types